Evidence map›Paper›PMID 32920777›Full record

ArticleOphthalmology and therapy2020

Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.

Asim V Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E Zaugg, Ashraf Z Badros and 8 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Asim V FarooqUniversity of Chicago Medical Center, Chicago, IL, USA. afarooq@bsd.uchicago.edu.
Simona Degli EspostiNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK.
Rakesh PopatUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Praneetha ThulasiEmory Eye Center, Emory University, Atlanta, GA, USA.
Sagar LonialEmory University, Winship Cancer Institute, Atlanta, GA, USA.
Ajay K NookaEmory University, Winship Cancer Institute, Atlanta, GA, USA.
Andrzej JakubowiakUniversity of Chicago Medical Center, Chicago, IL, USA.
Douglas SborovHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Brian E ZauggMoran Eye Center, University of Utah, Salt Lake City, UT, USA.
Ashraf Z BadrosUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Bennie H JengDepartment of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Natalie S CallanderUniversity of Wisconsin, Carbone Cancer Center, Madison, WI, USA.
Joanna OpalinskaGlaxoSmithKline, Upper Providence, PA, USA.
January BaronGlaxoSmithKline, Upper Providence, PA, USA.
Trisha PiontekGlaxoSmithKline, Upper Providence, PA, USA.
Julie ByrneGlaxoSmithKline, Upper Providence, PA, USA.
Ira GuptaGlaxoSmithKline, Upper Providence, PA, USA.
Kathryn ColbyUniversity of Chicago Medical Center, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The authors of the above mentioned article would like to highlight the following corrections, based upon recent changes to the FDA label and guidance on the use of belamaf.

Identifiers

PMID32920777
PMCPMC7708532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.